Individual generic drug information

aflibercept

Reference monograph

Part of registered formulation

AFLIBERCEPT

Reference record: aflibercept
Source: Mosby’s 2024 Nursing Drug Reference
Printed source pages: 42
Age groups indexed: Not recorded

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for aflibercept only.

Names and pronunciation

(a-fli-ber′sept) Eylea

Source page 42

Functional class

Func. class.: Vascular endothelial growth factor inhibitor signal transduc- tion inhibitor (STI) (ophthalmic)

Source page 42

Uses

USES: For treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema after central reti- nal vein occlusion, diabetic retinopathy with diabetic macular edema

Source page 42

Dose and formulations

Extracted information for aflibercept only.

Dosage and routes

DOSAGE AND ROUTES Neovascular age-related macular degeneration (wet) Adult: Intravitreal injection 2 mg (0.05 mL) into affected eye q4wk × 12 wk, then 2mg q8wk Diabetic macular edema/retinopathy Adult: Intravitreal injection 2 mg (0.05 mL) q4wk × 5 injections, then 2 mg (0.05 mL) q8wk Macular edema Adult: Intravitreal injection: 2 mg (0.05 mL) q4wk

Source page 42

Available forms

Available forms: Intravitreal injection 2 mg (0.05 mL) single-use vial • Adult: Intravitreal injection 2 mg (0.05 mL) into affected eye(s) q4wk × 12 wk, then 2 mg (0.05 mL) q8wk

Source page 42

Dose text by age group

Filter the extracted dose blocks for this individual drug.

No dose block was identified for this age filter. This does not establish whether the drug is suitable for that age group.

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

aflibercept

Reference monograph

Part of registered formulation

AFLIBERCEPT

Reference record: aflibercept
Source: Mosby’s 2024 Nursing Drug Reference
Printed source pages: 42
Age groups indexed: Not recorded

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for aflibercept only.

Names and pronunciation

(a-fli-ber′sept) Eylea

Source page 42

Functional class

Func. class.: Vascular endothelial growth factor inhibitor signal transduc- tion inhibitor (STI) (ophthalmic)

Source page 42

Uses

USES: For treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema after central reti- nal vein occlusion, diabetic retinopathy with diabetic macular edema

Source page 42

Dose and formulations

Extracted information for aflibercept only.

Dosage and routes

Source page 42

Available forms

Available forms: Intravitreal injection 2 mg (0.05 mL) single-use vial • Adult: Intravitreal injection 2 mg (0.05 mL) into affected eye(s) q4wk × 12 wk, then 2 mg (0.05 mL) q8wk

Source page 42

Dose text by age group

Filter the extracted dose blocks for this individual drug.

No dose block was identified for this age filter. This does not establish whether the drug is suitable for that age group.

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.